{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:04Z","timestamp":1787004784120,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1053\/j.ackd.2006.01.013","type":"journal-article","created":{"date-parts":[[2006,7,7]],"date-time":"2006-07-07T15:20:23Z","timestamp":1152285623000},"page":"138-147","source":"Crossref","is-referenced-by-count":18,"title":["Diagnosis and Management of Kidney Involvement in Fabry Disease"],"prefix":"10.1053","volume":"13","author":[{"given":"David G.","family":"Warnock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2006.01.013_bib1","series-title":"The Metabolic Bases of Inherited Disease","first-page":"3733","article-title":"Alpha-Galactosidase A deficiency","author":"Desnick","year":"2001"},{"key":"10.1053\/j.ackd.2006.01.013_bib2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.ackd.2006.01.013_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cccn.2004.10.019","article-title":"Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers","volume":"353","author":"Linthorst","year":"2005","journal-title":"Clin Chim Acta"},{"key":"10.1053\/j.ackd.2006.01.013_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease","volume":"337","author":"Garman","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1053\/j.ackd.2006.01.013_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/humu.9327","article-title":"Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease","volume":"25","author":"Schafer","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1053\/j.ackd.2006.01.013_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2796.2004.01300.x","article-title":"The expanding clinical spectrum of Anderson-Fabry disease","volume":"255","author":"Hauser","year":"2004","journal-title":"J Intern Med"},{"key":"10.1053\/j.ackd.2006.01.013_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/08035320510031045","article-title":"Genotype and phenotype in Fabry disease","volume":"94","author":"Schaefer","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1053\/j.ackd.2006.01.013_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/humu.9172","article-title":"Molecular analysis in Fabry disease in Spain","volume":"22","author":"Rodriguez-Mari","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1053\/j.ackd.2006.01.013_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5414\/CNP61185","article-title":"A nonsense mutation (R220X) in the alpha-galactosidase A gene causes typical Fabry disease in both genders","volume":"61","author":"Maki","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2006.01.013_bib10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.ejhg.5201184","article-title":"Remarkable variability in renal disease in a large Slovenian family with Fabry disease","volume":"12","author":"Verovnik","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"10.1053\/j.ackd.2006.01.013_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00041552-200503000-00002","article-title":"Fabry disease","volume":"14","author":"Warnock","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.ackd.2006.01.013_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"10.1053\/j.ackd.2006.01.013_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/A:1012475908718","article-title":"Renal disease in Fabry patients","volume":"24","author":"Grunfeld","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1053\/j.ackd.2006.01.013_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry\u2019s disease","volume":"13","author":"Gubler","year":"1978","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"10.1053\/j.ackd.2006.01.013_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1023\/A:1012423924648","article-title":"Renal pathological changes in Fabry disease","volume":"24","author":"Sessa","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1053\/j.ackd.2006.01.013_bib16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.5858\/2004-128-593-PQCAUC","article-title":"Pathologic quiz case: an unsuspected cause of nephrotic syndrome. Heterozygous Fabry disease","volume":"128","author":"Thamboo","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"10.1053\/j.ackd.2006.01.013_bib17","first-page":"634","article-title":"Treatment of three Fabry patients with moderate renal failure and description of the renal variant","volume":"18","author":"Torra","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.01.013_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004728-200403000-00002","article-title":"Fabry Disease","volume":"28","author":"Glass","year":"2004","journal-title":"J Comput Assist Tomogr"},{"key":"10.1053\/j.ackd.2006.01.013_bib19","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1523-1755.2004.00846.x","article-title":"Parapelvic kidney cysts","volume":"66","author":"Ries","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.01.013_bib20","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1053\/j.ajkd.2005.01.036","article-title":"Chronic renal failure and proteinuria in adulthood","volume":"45","author":"Cybulla","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.01.013_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s10157-005-0369-4","article-title":"Significance of screening for Fabry disease among male dialysis patients","volume":"9","author":"Ichinose","year":"2005","journal-title":"Clin Exp Nephrol"},{"key":"10.1053\/j.ackd.2006.01.013_bib22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.01.013_bib23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","article-title":"Results of a nationwide screening for Anderson-Fabry disease among dialysis patients","volume":"15","author":"Kotanko","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2006.01.013_bib24","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/ndt\/gfg194","article-title":"alpha-Galactosidase A deficiency in Dutch patients on dialysis","volume":"18","author":"Linthorst","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.01.013_bib25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1034\/j.1399-0004.2003.00077.x","article-title":"Analysis of splice-site mutations of the alpha-galactosidase A gene in Fabry disease","volume":"63","author":"Lai","year":"2003","journal-title":"Clin Genet"},{"key":"10.1053\/j.ackd.2006.01.013_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/376608","article-title":"Fabry disease","volume":"73","author":"Yasuda","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1053\/j.ackd.2006.01.013_bib27","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1373\/clinchem.2004.037937","article-title":"Immunoquantification of alpha-galactosidase","volume":"50","author":"Fuller","year":"2004","journal-title":"Clin Chem"},{"key":"10.1053\/j.ackd.2006.01.013_bib28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urinary lipid profiling for the identification of fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin Chem"},{"key":"10.1053\/j.ackd.2006.01.013_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1053\/j.ackd.2006.01.013_bib30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00041552-200403000-00012","article-title":"Renoprotection by enzyme replacement therapy","volume":"13","author":"Brenner","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.ackd.2006.01.013_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2006.01.013_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1053\/j.ackd.2006.01.013_bib33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.ackd.2006.01.013_bib34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/1568016043356192","article-title":"Efficacy of enzyme replacement therapy in Fabry disease","volume":"2","author":"Barbey","year":"2004","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"key":"10.1053\/j.ackd.2006.01.013_bib35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1053\/j.ackd.2006.01.013_bib36","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.01.013_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014Replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2006.01.013_bib38","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.01.013_bib39","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2006.01.013_bib40","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ackd.2006.01.013_bib41","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"10.1053\/j.ackd.2006.01.013_bib42","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease","volume":"34","author":"Beck","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1053\/j.ackd.2006.01.013_bib43","first-page":"1","article-title":"Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement","volume":"29","author":"Schiffmann","year":"2005","journal-title":"Virchows Arch"},{"key":"10.1053\/j.ackd.2006.01.013_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2014Role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1053\/j.ackd.2006.01.013_bib45","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease. Evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.01.013_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/08035320510028067","article-title":"Measurement of renal function in patients with Fabry disease","volume":"94","author":"Kleinert","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1053\/j.ackd.2006.01.013_bib47","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.ackd.2006.01.013_bib48","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.01.013_bib49","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5414\/CNP63394","article-title":"Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabrs disease","volume":"63","author":"Svarstad","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2006.01.013_bib50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.ASN.0000043901.45141.D4","article-title":"Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis","volume":"14","author":"Eitzman","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2006.01.013_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ndt\/18.1.33","article-title":"Enzyme replacement therapy in Anderson-Fabry\u2019s disease","volume":"18","author":"De Schoenmakere","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.01.013_bib52","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2006.01.013_bib53","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMcp011773","article-title":"Clinical practice. Nephropathy in patients with type 2 diabetes","volume":"346","author":"Remuzzi","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2006.01.013_bib54","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"10.1053\/j.ackd.2006.01.013_bib55","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00415-004-0364-9","article-title":"Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease","volume":"251","author":"Hilz","year":"2004","journal-title":"J Neurol"},{"key":"10.1053\/j.ackd.2006.01.013_bib56","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00415-003-1133-x","article-title":"Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease","volume":"250","author":"Stemper","year":"2003","journal-title":"J Neurol"},{"key":"10.1053\/j.ackd.2006.01.013_bib57","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1159\/000087675","article-title":"Cardiopulmonary exercise testing in Fabry disease","volume":"72","author":"Bierer","year":"2005","journal-title":"Respiration"},{"key":"10.1053\/j.ackd.2006.01.013_bib58","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1046\/j.1523-1755.2003.00832.x","article-title":"Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies","volume":"63","author":"Campbell","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.01.013_bib59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE)","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2006.01.013_bib60","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1046\/j.1523-1755.2003.00885.x","article-title":"The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy","volume":"63","author":"Keane","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.01.013_bib61","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","article-title":"Retarding progression of chronic renal disease","volume":"63","author":"Ruggenenti","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.01.013_bib62","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1681\/ASN.V10112426","article-title":"Dietary protein restriction and the progression of chronic renal disease","volume":"10","author":"Levey","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2006.01.013_bib63","first-page":"142","article-title":"Sustained decrease in urine protein excretion in Fabry patients treated with ACE ihibitors and ARBs while receiving agalsidase-beta therapy","volume":"16","author":"Tahir","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2006.01.013_bib64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.01.013_bib65","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1523-1755.2004.00440.x","article-title":"Fabry disease","volume":"65","author":"Siamopoulos","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.01.013_bib66","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1523-1755.2004.00883.x","article-title":"Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease","volume":"66","author":"Kosch","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.01.013_bib67","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","article-title":"Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease","volume":"65","author":"Mignani","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.01.013_bib68","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000060191","article-title":"Long-term survival of patients with renal transplantation in Fabry\u2019s disease","volume":"136","author":"Mignani","year":"2001","journal-title":"Contrib Nephrol"},{"key":"10.1053\/j.ackd.2006.01.013_bib69","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","article-title":"Excellent outcome of renal transplantation in patients with Fabry\u2019s disease","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"issue":"Suppl 7","key":"10.1053\/j.ackd.2006.01.013_bib70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/11.supp7.4","article-title":"Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry","volume":"11","author":"Tsakiris","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.01.013_bib71","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jchromb.2004.03.037","article-title":"Optimisation of the separation of four major neutral glycosphingolipids","volume":"805","author":"Roy","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1053\/j.ackd.2006.01.013_bib72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1447-0756.1985.tb00045.x","article-title":"Early prenatal diagnosis of inborn error of metabolism","volume":"11","author":"Tsutsumi","year":"1985","journal-title":"Asia Oceania J Obstet Gynaecol"},{"key":"10.1053\/j.ackd.2006.01.013_bib73","first-page":"85","article-title":"Diagnostic value of kidney biopsy in heterozygous Fabry\u2019s disease","volume":"109","author":"Farge","year":"1985","journal-title":"Arch Pathol Lab Med"},{"key":"10.1053\/j.ackd.2006.01.013_bib74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000247189","article-title":"Fabry\u2019s disease","volume":"187","author":"Marguery","year":"1993","journal-title":"Dermatology"},{"key":"10.1053\/j.ackd.2006.01.013_bib75","first-page":"89","article-title":"Fabry\u2019s disease in a heterozygous woman","volume":"109","author":"Rodriguez","year":"1985","journal-title":"Arch Pathol Lab Med"},{"key":"10.1053\/j.ackd.2006.01.013_bib76","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000060188","article-title":"Heterozygotes with Fabry\u2019s disease","volume":"136","author":"Grunfeld","year":"2001","journal-title":"Contrib Nephrol"},{"key":"10.1053\/j.ackd.2006.01.013_bib77","first-page":"71","article-title":"Subclinical Fabry\u2019s disease occurring in the context of IgA nephropathy","volume":"47","author":"Kawamura","year":"1997","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2006.01.013_bib78","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/ndt\/12.1.221","article-title":"Isolated glomerular proteinuria as the only clinical manifestation of Fabry\u2019s disease in an adult male","volume":"12","author":"Meroni","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.01.013_bib79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","article-title":"Improvement in cardiac function in the cardiac variant of Fabry\u2019s disease with galactose-infusion therapy","volume":"345","author":"Frustaci","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1053\/j.ackd.2006.01.013_bib80","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1012455421014","article-title":"Gene therapy for Fabry disease","volume":"24","author":"Siatskas","year":"2001","journal-title":"J Inherit Metab Dis"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559506000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559506000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T06:39:11Z","timestamp":1627540751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559506000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S1548559506000140"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2006.01.013","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}